BUGATTI, Antonella
 Distribuzione geografica
Continente #
NA - Nord America 6.065
EU - Europa 4.212
AS - Asia 2.625
SA - Sud America 486
Continente sconosciuto - Info sul continente non disponibili 169
AF - Africa 74
OC - Oceania 21
Totale 13.652
Nazione #
US - Stati Uniti d'America 5.922
PL - Polonia 2.455
CN - Cina 911
SG - Singapore 814
UA - Ucraina 405
BR - Brasile 402
DE - Germania 293
HK - Hong Kong 262
IT - Italia 262
VN - Vietnam 251
FI - Finlandia 197
GB - Regno Unito 157
FR - Francia 122
TR - Turchia 88
CA - Canada 84
RU - Federazione Russa 84
IE - Irlanda 76
IN - India 75
BD - Bangladesh 46
ID - Indonesia 36
SE - Svezia 28
MX - Messico 25
AR - Argentina 23
IQ - Iraq 23
ZA - Sudafrica 23
AU - Australia 21
CZ - Repubblica Ceca 19
ES - Italia 19
JP - Giappone 17
NL - Olanda 17
AT - Austria 16
EC - Ecuador 14
VE - Venezuela 13
BE - Belgio 11
SA - Arabia Saudita 11
CL - Cile 10
NG - Nigeria 10
PK - Pakistan 10
CR - Costa Rica 9
PE - Perù 9
UZ - Uzbekistan 9
EG - Egitto 8
JM - Giamaica 8
JO - Giordania 8
KE - Kenya 8
MA - Marocco 8
AE - Emirati Arabi Uniti 7
DZ - Algeria 6
EU - Europa 6
LT - Lituania 6
PT - Portogallo 6
UY - Uruguay 6
AZ - Azerbaigian 5
CH - Svizzera 5
CO - Colombia 5
DK - Danimarca 5
KZ - Kazakistan 5
LK - Sri Lanka 5
MY - Malesia 5
OM - Oman 5
TN - Tunisia 5
TW - Taiwan 5
BG - Bulgaria 4
IR - Iran 4
MD - Moldavia 4
NP - Nepal 4
TH - Thailandia 4
EE - Estonia 3
HN - Honduras 3
HR - Croazia 3
KG - Kirghizistan 3
KR - Corea 3
PA - Panama 3
PH - Filippine 3
PS - Palestinian Territory 3
PY - Paraguay 3
TT - Trinidad e Tobago 3
AL - Albania 2
DO - Repubblica Dominicana 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CU - Cuba 1
CY - Cipro 1
ET - Etiopia 1
GT - Guatemala 1
HU - Ungheria 1
IS - Islanda 1
KW - Kuwait 1
LC - Santa Lucia 1
LV - Lettonia 1
MK - Macedonia 1
MM - Myanmar 1
NI - Nicaragua 1
NO - Norvegia 1
Totale 13.485
Città #
Warsaw 2.452
Ashburn 602
Fairfield 549
Singapore 431
San Jose 341
Woodbridge 325
Houston 305
Jacksonville 282
Hong Kong 261
Chandler 235
Cambridge 221
Seattle 217
Beijing 211
Wilmington 195
Ann Arbor 191
Council Bluffs 189
Dallas 181
The Dalles 176
New York 150
Princeton 131
Helsinki 122
Los Angeles 114
Dong Ket 87
Nanjing 84
Brescia 77
Dublin 75
Munich 70
Istanbul 69
Lauterbourg 65
Ho Chi Minh City 58
Columbus 53
Santa Clara 46
Jinan 42
Porto Alegre 41
San Francisco 39
Shanghai 39
Nanchang 37
Phoenix 37
Boardman 36
São Paulo 35
Des Moines 32
Chicago 30
Dearborn 30
Changsha 29
San Diego 29
Hebei 28
Toronto 28
Hanoi 27
Milan 27
Shenyang 27
Redondo Beach 26
Buffalo 25
Jakarta 24
Orem 24
London 22
Tianjin 22
Hangzhou 21
Moscow 20
Johannesburg 19
Atlanta 18
Jiaxing 18
Montreal 18
Stockholm 18
Turku 18
Parma 17
Springfield 17
Guangzhou 16
Brooklyn 15
Denver 15
Manchester 15
Tokyo 15
Brno 14
Charlotte 14
Lancaster 14
Zhengzhou 14
Chennai 13
Haikou 12
Boston 11
Curitiba 11
Frankfurt am Main 11
Nuremberg 11
Abuja 10
Rio de Janeiro 10
Verona 10
Amsterdam 9
Lanzhou 9
Miami 9
Mumbai 9
Brussels 8
Kilburn 8
Kunming 8
Mexico City 8
Rome 8
Salt Lake City 8
San José 8
Tashkent 8
Vancouver 8
Amman 7
Baghdad 7
Belo Horizonte 7
Totale 9.845
Nome #
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Epheephrin system 397
Bridging the past and the future of virology: Surface plasmon resonance as a powerful tool to investigate virus/host interactions. 372
alphavbeta3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers. 335
Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. 331
Membrane association of peroxiredoxin-2 in red cells is mediated by n-terminal cytoplasmic domain of band 3 326
BSA conjugates bearing multiple copies of the basic domain of HIV-1 Tat: prototype for the development of multitarget inhibitors of extracellular Tat 325
Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use 324
Biological role of immunoglobulin Free light chains interactomes 317
Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived antiangiogenic pentapeptide. 313
Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric Ligands 301
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery 298
Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance 291
Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. 281
Pradamicin A: a new therapeutic concept for tretment of virus infections with a glycosilated envelope such as human immunodeficiency virus 271
Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors 266
Inhibition of Non Canonical HIV-1 Tat Secretion Through the Cellular Na+,K+-ATPase Blocks HIV-1 Infection 264
A complex of α(6) integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6. 255
The AGMA1 poly(amidoamine) inhibits the infectivity of herpes simplex virus in cell lines, in human cervicovaginal histocultures, and in vaginally infected mice 255
Chemoselective surface immbolization of proteins through a cleavable peptide 247
Functionalization of gold surfaces with copoly(DMA-NAS-MAPS) by dip coating: Surface characterization and hybridization tests 240
Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of HIV-1 Tat and gp120 proteins 234
The agmatine-containing poly(Amidoamine) polymer AGMA1 binds cell surface heparan sulfates and prevents attachment of mucosal human papillomaviruses 230
Molecular Interaction Studies of HIV-1 Matrix Protein p17 and Heparin: IDENTIFICATION OF THE HEPARIN-BINDING MOTIF OF p17 AS A TARGET FOR THE DEVELOPMENT OF MULTITARGET ANTAGONISTS 225
A CXCR1 haplotype hampers HIV-1 matrix protein p17 biological activity 210
Merging colloidal nanoplasmonics and surface plasmon resonance spectroscopy for enhanced profiling of multiple myeloma-derived exosomes 201
Cellular aspartyl proteases promote the unconventional secretion of biologically active HIV-1 matrix protein p17 188
The thymidine phosphorylase inhibitor 5'-O-tritylinosine (KIN59) is an anti-angiogenic multi-target fibroblast growth factor-2 antagonist. 186
Role of Nanomechanics in Canonical and Noncanonical Pro-angiogenic Ligand/VEGF Receptor-2 Activation 183
Heparin and heparan sulfate proteoglycans promote HIV-1 p17 matrix protein oligomerization: computational, biochemical and biological implications 182
A persistently replicating SARS-CoV-2 variant derived from an asymptomatic individual 175
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 174
HIV-1 matrix protein p17 binds to the IL-8 receptor CXCR1 and shows IL-8-like chemokine activity on monocytes through Rho/ROCK activation 168
Mycoplasma infection may complicate the clinical course of SARS-Co-V-2 associated Kawasaki-like disease in children 158
alpha v beta 3 integrin-dependent activation of focal adhesion kinase mediates NF-kB activation and motogenic activity by HIV-1 Tat in endothelial cells 156
Angiostatic, tumor inflammatory and anti-tumor effects of CXCL4(47-70) and CXCL4L1(47-70) in an EGF-dependent breast cancer model. 156
The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2) 153
Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity 152
Plasmonic exosomes for enhanced monitoring of monoclonal gammopathies 152
Therapeutic Potential of Anti-Angiogenic Multitarget N,O-Sulfated E. Coli K5 Polysaccharide in Diabetic Retinopathy 151
HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2 150
The synthetic dipeptide pidotimod shows a chemokine-like activity through cxc chemokine receptor 3 (Cxcr3) 141
Avian Reovirus P17 Suppresses Angiogenesis by Promoting DPP4 Secretion 139
Sulfated K5 Escherichia coli polysaccharide derivatives as wide range inhibitors of genital types of human papillomavirus 137
B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation 136
Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding Peptide. 132
Binding to PI(4,5)P2 is indispensable for secretion of B-cell clonogenic HIV-1 matrix protein p17 variants 132
Direct and Allosteric Inhibition of the FGF2/HSPGs/FGFR1 Ternary Complex Formation by an Antiangiogenic, Thrombospondin-1-Mimic Small Molecule. 131
Angiogenic growth factor-endothelial cell interaction: receptor binding and cell internalization techniques 129
Surface plasmon resonance analysis of heparin-binding angiogenic growth factors 128
Methotrexate inhibits SARS-CoV-2 virus replication “in vitro” 128
endothelial cell adhesion to HIV-1 Tat: cross talk between integrin alphav beta3 and vascular endothelial growth factor receptor-2 (KDR) 126
Peptide-Derivatized SB105-A10 Dendrimer Inhibits the Infectivity of R5 and X4 HIV-1 Strains in Primary PBMCs and Cervicovaginal Histocultures 126
Positively charged peptides can interact with each other as revealed by solid phase binding assays 124
Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses 124
HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide 116
EXPLOTING SURFACE PLASMON RESONANCE (SPR) TECHNOLOGY FOR THE IDENTIFICATION OF FIBROBLAST GROWTH FACTOR-2 (FGF2) ANTAGONISTS ENDOWED WITH ANTI-ANGIOGENIC ACTIVITY 116
Evolution toward beta common chain receptor usage links the matrix proteins of HIV-1 and its ancestors to human erythropoietin 116
Sars-cov-2 infection remodels the phenotype and promotes angiogenesis of primary human lung endothelial cells 116
FGF2- Antagonist activity of long pentraxin-3 115
FGF2-Antagonist activity of long pentraxin-3 related peptides 113
Role of autophagy in von willebrand factor secretion by endothelial cells and in the in vivo thrombin-antithrombin complex formation promoted by the hiv-1 matrix protein p17 108
Competition for dominance within replicating quasispecies during prolonged SARS-CoV-2 infection in an immunocompromised host 105
DHFR Inhibitors Display a Pleiotropic Anti-Viral Activity against SARS-CoV-2: Insights into the Mechanisms of Action 100
Human Metapneumovirus Establishes Persistent Infection in Lung Microvascular Endothelial Cells and Primes a Th2-Skewed Immune Response 95
The NLS of the HIV-1 Tat protein interacts with the fd bacteriophage and with a peptide derived from its p8 protein 94
inhibition of intra- and extra-cellular Tat function and HIV expression by pertussin toxin B-oligomer 90
SARS-CoV-2 Infects Human ACE2-Negative Endothelial Cells through an αvβ3 Integrin-Mediated Endocytosis Even in the Presence of Vaccine-Elicited Neutralizing Antibodies 89
Identification of an anti-angiogenic FGF2-binding site in the n-terminal extension of the soluble pattern recognition receptor long-pentraxin PTX3 89
Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants 89
development of novel small molecules mimicking thrombospondin-1 (TSP-1) antiangiogenic activity 88
exploiting surface plasmon resonance technology for the identification of fibroblast growth factor 2 (FGF2) antagonists endowed with antiangiogenic activity 87
Temporal viral loads in respiratory and gastrointestinal tract and serum antibody responses during SARS-CoV-2 infection in an Italian pediatric cohort 85
The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5 Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung Microvascular Endothelial Cells 83
Emergence of S gene-based quasispecies explains an optimal adaptation of Omicron BA.5 subvariant in the immunocompetent vaccinated human host 76
heparin and heparan sulfate proteoglycans promotes hiv-1 p17 matrix protein oligomerization: computational, biochemical and biological implications 68
Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions 67
A broad-spectrum anti-angiogenic tetrapeptide regresses diabetic retinopathy through β-arrestin-1 binding and prevention of Akt phosphorylation 38
A Dynamic and Effective Peptide-Based Strategy for Promptly Addressing Emerging SARS-CoV-2 Variants of Concern 35
Molecular mechanisms behind the generation of pro-oncogenic HIV-1 matrix protein p17 variants 26
Heparan sulfate proteoglycans remodel SARS-CoV-2 spike conformation to allow integrin interaction and infection of endothelial cells 22
Totale 13.652
Categoria #
all - tutte 56.343
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.343


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022428 0 0 0 18 16 15 32 46 33 72 59 137
2022/2023565 75 30 22 35 52 136 2 77 85 3 28 20
2023/2024699 44 10 61 39 42 116 31 27 152 28 31 118
2024/20251.384 15 9 11 226 108 119 78 61 154 136 275 192
2025/20263.407 249 354 340 474 327 242 535 147 202 324 94 119
2026/2027725 123 140 226 236 0 0 0 0 0 0 0 0
Totale 13.652